| Literature DB >> 35739893 |
Débora Gouveia1,2, Ana Cardoso1, Carla Carvalho1, Ana Rita Gonçalves3, Óscar Gamboa4, Rute Canejo-Teixeira3, António Ferreira4,5, Ângela Martins1,2,3,5.
Abstract
Acute noncompressive nucleus pulposus extrusion (ANNPE) is related to contusive spinal cord injuries, and dogs usually appear to be exercising vigorously at the time of onset. ANNPE has a characteristic peracute onset of clinical signs during exercise or following trauma, with non-progressive signs during the first 24 h and possibly signs of spinal shock. The main aim was to assess if the presence of spinal shock affects the neurorehabilitation outcomes of ANNPE dogs. This prospective controlled cohort clinical study was conducted at the Arrábida Rehabilitation Center. All of the dogs had T3-L3 injuries and were paraplegic/monoplegic with/without nociception, the study group (n = 14) included dogs with ANNPE spinal shock dogs, and the control group (n = 19) included ANNPE dogs without spinal shock. The study group was also evaluated using a new scale-the Spinal Shock Scale (SSS)-and both groups were under the same intensive neurorehabilitation protocol. Spinal shock was a negative factor for a successful outcome within less time. SSS scores > 4 required additional hospitalization days. The protocol was safe, tolerable, and feasible and accomplished 32% ambulation within 7 days, 29% in 14 days, and 29% in 30 days. The results were better than those obtained in previous studies-94% at 60 days-and 75% of the dogs without nociception recovered ambulation. Long-term follows-ups carried out 4 years later revealed a positive evolution.Entities:
Keywords: ANNPE; dogs; neurorehabilitation; nociception; spinal shock; spinal shock scale
Year: 2022 PMID: 35739893 PMCID: PMC9219513 DOI: 10.3390/ani12121557
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 3.231
Figure 1Computed Tomography–Myelogram image from a 6-year-old Labrador with T12–T13 acute non-compressive nucleus pulposus extrusion. (A) Vacuum phenomenon and light attenuation of the ventral contrast line diameter (sagittal view); (B) T12–T13 hyperintensity sign and bilateral light attenuation of the diameter of the contrast lines (dorsal view); (C) normal T12–T13 disk space with residual mineralized disk material ventrally (transverse view).
Sample characterization of both the control and study groups.
| SG | CG | Total | |
|---|---|---|---|
| Breed | Breed: 64.3% (9/14) | Breed: 89.5% (17/19) | Breed: 78.8% (26/33) |
| Mixed Breed: 35.7% (5/14) | Mixed Breed: 10.5% (2/19) | Mixed Breed: 21.2% (7/33) | |
| Sex | Male: 50% (7/14) | Male: 57.9% (11/19) | Male: 54.5% (18/33) |
| Female: 50% (7/14) | Female: 42.1% (8/19) | Female: 45.5% (15/33) | |
| Age | <7 years old: 71.4% (10/14) | <7 years old: 57.9% (11/19) | <7 years old: 63.6% (21/33) |
| ≥7 years old: 28.6% (4/14) | ≥7 years old: 42.1% (8/19) | ≥7 years old: 36.4% (12/33) Mean: 6 years | |
| Mean: 5.64 years | Mean: 6.42 years | ||
| Weight | ≤15 kg: 35.7% (5/14) | ≤15 kg: 36.8% (7/19) | ≤15 kg: 36.4% (12/33) |
| >15 kg: 64.3% (9/14) | >15 kg: 63.2% (12/19) | >15 kg: 63.6% (21/33) | |
| Mean: 26.86 kg | Mean: 21.89 kg | Mean: 24 kg. | |
| Complementary Exams | MRI: 35.7% (5/14) | MRI: 42.1% (8/19) | MRI: 39.4% (13/33) |
| CT: 64.3% (9/14) | CT: 57.9% (11/19) | CT: 60.6% (20/33) | |
| Neuroanatomical Localization | T12–T13: 14.3% (2/14) | T12–T13: 21.1% (4/19) | T12–T13: 18.2% (6/33) |
| T13–L1: 35.7% (5/14) | T13–L1: 36.8% (7/19) | T13–L1: 36.4% (12/33) | |
| L1–L2: 21.4% (3/14) | L1–L2: 31.6% (6/19) | L1–L2: 27.3% (9/33) | |
| L2–L3: 28.6% (4/14) | L2–L3: 10.5% (2/19) | L2–L3: 18.2% (6/33) | |
| Lateralization signs | Absent: 14.3% (2/14) | Absent: 21.1% (4/19) | Absent: 18.2% (6/33) |
| Present: 85.7% (12/14) | Present: 78.9% (15/19) | Present: 81.8% (27/33) | |
| Spinal discomfort | Absent: 78.6% (11/14) | Absent: 84.2% (16/19) | Absent: 81.8% (27/33) |
| Present: 21.4% (3/14) | Present: 15.8% (3/19) | Present: 18.2% (6/33) | |
| Nociception | Absent: 28.6% (4/14) | Absent: 21.1% (4/19) | Absent: 24.2% (8/33) |
| Present: 71.4% (10/14) | Present: 78.9% (15/19) | Present: 75.8% (25/33) | |
| Modified | Grade 0: 28.6% (4/14) | Grade 0: 21.1% (4/19) | Grade 0: 24.2% (8/33) |
| Grade 1: 71.4% (10/14) | Grade 1: 78.9% (15/19) | Grade 1: 75.8% (25/33) | |
| Fecal and Urinary Incontinence | Present: 14% (2/14) (progressive myelomalacia) | Absent: 100% (19/19) | Present: 6% (2/33) (progressive myelomalacia) |
| Absent: 86% (12/14) | Absent: 94% (31/33) | ||
| Occurrences | Absent: 28.6% (4/14) | Absent: 57.9% (11/19) | Absent: 45.5% (15/33) |
Legend: SG (study group); CG (control group).
Spinal Shock Scale (SSS).
| Reduced hindlimb reflexes | Withdrawal reflex | (+1) |
| Patellar reflex | (+1) | |
| Cranial tibial reflex | (+1) | |
| Reduced hindlimb tone | (+1) | |
| Reduced perineal reflex | (+1) | |
| Reduced perineal tone | (+1) | |
| Absent/abnormal cutaneous trunci cut off | (+1) | |
| TOTAL SCORE | ||
Figure 2Electrical stimulation protocols on a dog in a postural standing position. (A) Co-contraction protocol with the stimulation of both the quadriceps femoris group and the hamstring muscles group. (B) Segmental technique of the sciatic nerve by means of functional electrical stimulation.
Intensive neurorehabilitation protocol.
| KERRYPNX | Electrical Stimulation | Laser Therapy Class IV | Kinesiotherapy Exercises | ||||
|---|---|---|---|---|---|---|---|
| Land Treadmill | Underwater Treadmill | Exercises | |||||
| Admission to Ambulation | Study Group | DPP Positive | 50 Hz, 10 mA, 150 μs, duty cycle 1:4; | After trichotomy, 12 J/cm2, 2,5 Hz, duty cycle 88%, 3 min, pulsed mode, SID, 15 days. | 3–10 min; | 5–10 min; | Obstacle rails, postural standing: 1–2 min, 3–6 times/day; |
| no slope; | no slope; | bicycles: 2–3 times/day | |||||
| 1.8 km/h | 1.2–2 km/h | alternating floors: 1 min, 3–6 times/day, | |||||
| 10 min; TID; | 4–6 times/day; | SID; | 6 days/week. | ||||
| SSS score < 4; BID. | 6 days/week. | 5 days/week. | |||||
| DPP Negative | 40 Hz; 10–48 mA; 150 μs, | 3–10 min; | 10–20 min; | Obstacle rails, postural standing: 1–2 min, 3–6 times/day; | |||
| no slope; | |||||||
| duty cycle 1:4. | 2–5% slope; 1.5 km/h | 1.2–2 km/h | bicycles: 2–3 times/day; | ||||
| 10 min; TID | 6–8 times/day; | SID; | alternating floors: 1 min, 3–6 times/day, | ||||
| SSS score < 4; BID. | 6 days/week. | 5 days/week. | 6 days/week | ||||
| Control Group | DPP Positive | 50 Hz; 10 mA; 150 μs, duty cycle 1:4; | 3–10 min; | 5–10 min; | Obstacle rails, postural standing: 1–2 min, 3–6 times/day; | ||
| no slope; | no slope; | bicycles: 2–3 times/day; | |||||
| 1.8 km/h | 1.2–2 km/h | alternating floors: 1 min, 3–6 times/day, | |||||
| 4–6 times/day; | SID; | 6 days/week. | |||||
| 10 min; BID. | 6 days/week. | 5 days/week. | |||||
| DPP Negative | 40 Hz; 10–48 mA; 150 μs, | 3–10 min; | 10–20 min; | Obstacles rails, postural standing: 1–2 min, 3–6 times/day; | |||
| 2–5% slope; 1.5 km/h | no slope; | bicycles: 2–3 times/day; | |||||
| 6–8 times/day; | 1.2–2 km/h | alternating floors: 1 min, 3–6 times/day, | |||||
| duty cycle 1:4; | 6 days/week. | SID; | 6 days/week. | ||||
| 10 min; BID. | 5 days/week. | ||||||
| Ambulation to Clinical Discharge | Study Group | DPP Positive | 50 Hz; 10 mA; 150 μs, duty cycle 1:4; | 10–40 min; | 30 min; | Obstacle rails, postural standing: 1–2 min, 2–3 times/day; | |
| 2–5% slope; 2–2.5 km/h | 2–5% slope; | alternating floors: 2 min, 2–3 times/day, | |||||
| 2–3 times/day; | 2–2.5 km/h | 3 days/week. | |||||
| 3 days/week. | SID; | ||||||
| 10 min; SID. | 3 days/week. | ||||||
| DPP Negative | 40 Hz; 10–48 mA; 150 μs, | 10–40 min; | 40 min; | Obstacle rails, postural standing: 1–2 min, 3 times/day; | |||
| duty cycle 1:4; | 2–5% slope; 1.8–2.5 km/h | 5–10% slope; | alternating floors: 2 min, 3 times/day, | ||||
| 10 min; SID. | 2–3 times/day; | 2.8–4.5 km/h | 5 days/week. | ||||
| 5 days/week. | SID; | ||||||
| 5 days/week. | |||||||
| Control Group | DPP Positive | 50 Hz; 10 mA; 150 μs, duty cycle 1:4; | 10–40 min; | Obstacle rails, postural standing: 1–2 min, 2–3 times/day; | |||
| 2–5% slope; 2–2.5 km/h | 30 min; | alternating floors: 2 min, 2–3 times/day, | |||||
| 2–3 times/day; | 2–5% slope; | 3 days/week. | |||||
| 3 days/week. | 2–2.5 km/h | ||||||
| SID; | |||||||
| 10 min; SID. | 3 days/week. | ||||||
| DPP Negative | 40 Hz; 10–48 mA; 150 μs, | 10–40 min; | 40 min; | Obstacle rails, postural standing: 1–2 min, 3 times/day; | |||
| 2–5% slope; 1.8–2.5 km/h | 5–10% slope; | alternating floors: 2 min, 3 times/day, | |||||
| 2–3 times/day; | 2.8–4.5 km/h | 5 days/week. | |||||
| duty cycle 1:4; | 5 days/week. | SID; | |||||
| 10 min; SID. | 5 days/week. | ||||||
Legend: DPP (deep pain perception); TID (three times a day); BID (twice a day); SID (once daily).
Figure 3Laser therapy class IV program applied on the spinal cord injury.
Figure 4Laser therapy class IV program applied to the coxofemoral joint using the four-point technique. (A) Proximo cranial region; (B) proximo caudal region; (C) disto caudal region; (D) disto cranial region.
Figure 5Locomotor exercise in two dogs. (A) Land treadmill; (B) underwater treadmill.
Figure 6Kinesiotherapy exercises. (A) Obstacle rail; (B) gait stimulation on alternating floors; knuckling position.
Figure 7Kinesiotherapy exercises. (A) Postural standing on a balance board; (B) bicycle movements on a central stimulation pad.
Figure 8Supportive treatment. (A) Passive range of motion exercises for the knee joint; (B) deep kneading massage technique for direct muscular treatment.
Figure 9Flow cohort diagram describing the outcome measures of both the control and study group throughout the rehabilitation period and after clinical discharge. OFS: Open Field Score; SSS: Spinal Shock Scale; CG: control group; SG: study group; T0 (day 0); T1 (day 1); T2 (day 2); T3 (day 3); T4 (day 5); T5 (day 7); T6 (day 14); T7 (day 21); T8 (day 30); T9 (day 60); F1 (7 days); F2 (15 days); F3 (one month); F4 (three months); F5 (six months); F6 (one year); F7 (two years); F8 (three years); F9 (four years).
Descriptive analysis of age and weight in both the study and control group.
|
|
|
| ||
| Age (years) | Mean | 5.64 | 6.42 | 6.09 |
| Median | 5 | 6 | 6 | |
| Variance | 5.94 | 9.48 | 7.898 | |
| SD | 2.437 | 3.079 | 2.81 | |
| Minimum | 2 | 1 | 1 | |
| Maximum | 11 | 12 | 12 | |
| SEM | 0.654 | 0.706 | 0.489 | |
| Shapiro–Wilk Normality Test | 0.55 | 0.326 | 0.088 | |
| Weight (kg) | Mean | 26.86 | 21.89 | 24 |
| Median | 24 | 21 | 21 | |
| Variance | 242.44 | 206.655 | 220.938 | |
| SD | 15.57 | 14.375 | 14.864 | |
| Minimum | 8 | 4 | 4 | |
| Maximum | 60 | 57 | 60 | |
| SEM | 4.161 | 3.298 | 2.587 | |
| Shapiro–Wilk Normality Test | 0.31 | 0.149 | 0.127 | |
Legend: SG (study group); CG (control group); SD (standard deviation); SEM (standard error of mean).
Figure 10Evolution of the spinal shock scale-estimated marginal means in the study group throughout the intensive neurorehabilitation process. Y-axis: Spinal shock scale score; T0 (day 0); T1 (day 1); T2 (day 2); T3 (day 3); T4 (day 5); T5 (day 7); T6 (day 14); T7 (day 21); T8 (day 30); T9 (day 60).
Evolution of the SSS score in the study group over time.
| Time Points | T0 | T1 | T2 | T3 | T4 | T5 | T6 | T7 | T8 | T9 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ID | |||||||||||
|
| 6 | 2 | 2 | 1 | 1 | 1 | |||||
|
| 6 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | |||
|
| 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | ||
|
| 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | |||
|
| 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||
|
| 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | |||
|
| 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | ||
|
| 3 | 2 | 1 | 1 | 1 | 1 | 1 | ||||
|
| 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | |||
|
| 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | |
|
| 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | |||
|
| 3 | 2 | 1 | 1 | 1 | 1 | 1 | ||||
|
| 7 | 6 | 6 | 6 | 7 | 7 | 7 | ||||
|
| 7 | 6 | 7 | 7 | 7 | ||||||
Legend: SSS (Spinal Shock Scale); ID (identification); T0 (day 0); T1 (day 1); T2 (day 2); T3 (day 3); T4 (day 5); T5 (day 14); T6 (day 14); T7 (day 21); T8 (day 30); T9 (day 60).
Figure 11Evolution of the Open Field Score (OFS)-estimated marginal means in both the study and control groups throughout intensive neurorehabilitation. Y-axis: OFS; T0 (day 0); T1 (day 1); T2 (day 2); T3 (day 3); T4 (day 5); T5 (day 7); T6 (day 14); T7 (day 21); T8 (day 30); T9 (day 60).
Figure 12Evolution of the OFS-estimated marginal means in both the study and control groups during the follow-up periods. Y-axis: OFS (Open Field Score); F1 (7 days); F2 (15 days), F3 (one month), F4 (three months), F5 (six months), F6 (one year), F7 (two years), F8 (three years); F9 (four years).